US20080183016A1 - Process for the synthesis of O-desmethylvenlafaxine - Google Patents

Process for the synthesis of O-desmethylvenlafaxine Download PDF

Info

Publication number
US20080183016A1
US20080183016A1 US11/881,826 US88182607A US2008183016A1 US 20080183016 A1 US20080183016 A1 US 20080183016A1 US 88182607 A US88182607 A US 88182607A US 2008183016 A1 US2008183016 A1 US 2008183016A1
Authority
US
United States
Prior art keywords
oba
acid
preparing
coba
odv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/881,826
Inventor
Valerie Niddam-Hildesheim
Tamar Nidam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals USA Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/881,826 priority Critical patent/US20080183016A1/en
Assigned to TEVA PHARMACEUTICAL INDUSTRIES LTD. reassignment TEVA PHARMACEUTICAL INDUSTRIES LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NIDDAM-HILDESHEIM, VALERIE, NIDAM, TAMAR
Assigned to TEVA PHARMACEUTICALS USA, INC. reassignment TEVA PHARMACEUTICALS USA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TEVA PHARMACEUTICAL INDUSTRIES LTD.
Publication of US20080183016A1 publication Critical patent/US20080183016A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/29Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Definitions

  • the invention encompasses a process for the synthesis of O-desmethylvenlafaxine.
  • Venlafaxine acts by inhibiting re-uptake of norepinephrine and serotonin, and is an alternative to the tricyclic anti-depressants and selective re-uptake inhibitors.
  • O-desmethylvenlafaxine 4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol, of the following formula,
  • MCC methyl benzyl cyanide
  • CMBC cyclohexyl methylbenzyl cyanide
  • DDMV didesmethyl venlafaxine
  • ODV O-desmethylvenlafaxine
  • U.S. Pat. No. 6,689,912 describes demethylation process performed by using a salt of high molecular weight alkane, arene, or arylalkyl thiolate anion in the presence of protic or aprotic solvent.
  • the salt can be prepared separately and then react with venlafaxine, or can react in-situ with venlafaxine.
  • the solvent, methanol should be removed. This operation is very complicated because the mixture containing the salt is highly viscous, hence the operation necessitate long time even under high vacuum.
  • the reaction is performed in-situ via removal of methanol in situ, this operation is still tedious and only partially successful, since it is difficult to reach the high temperature that the reaction necessitate to advance.
  • the described ODV synthesis processes are all indirect, i.e; performed via Venlafaxine.
  • the present invention provides a direct synthesis of O-desmethylvenlafaxine; i.e.; without passing through venlafaxine as an intermediate.
  • the invention encompasses hydroxyphenyl dimethylamide (OBA), having the following formula,
  • the present invention provides a process for preparing hydroxyphenyl dimethylamide (OBA) comprising combining hydroxybenzyl carboxy (OBCarboxy), a catalyst and an acid activating agent to obtain an activated acid; recovering the activated acid, and combining it with a dimethylamine to obtain OBA.
  • OBA hydroxyphenyl dimethylamide
  • the process for preparing OBA is done in the presence of an organic solvent.
  • the present invention provides a process for preparing ODV by preparing OBA as described above, and converting it to ODV.
  • OBA can be transformed to ODV via another intermediated such as COBA.
  • the present invention encompasses hydroxy protected OBA (POBA), having the following formula,
  • the present invention encompasses a process for preparing POBA comprising; combining OBA with a hydroxyl protecting agent and a base.
  • the present invention provides a process for preparing ODV by preparing POBA as described above, and converting it to ODV.
  • POBA can be transformed to ODV via another intermediated such as PCOBA.
  • the present invention encompasses cyclohexylOBA (COBA), having the following formula,
  • the process for the preparation of cyclohexylOBA comprising: reacting OBA with cyclohexanone and a base able to form a carbanion; and recovering the obtained COBA.
  • the present invention provides a process for preparing ODV by preparing COBA as described above, and converting it to ODV, by any method known in the art, i.e: the method described above.
  • the present invention encompasses a hydroxyl protected COBA (PCOBA), having the following formula,
  • the process for preparing PCOBA comprising; combining POBA with cyclohexanone and a base able to form a carbanion; and recovering the obtained PCOBA.
  • the present invention provides a process for preparing ODV by preparing PCOBA as described above and converting it to ODV, by any method known in the art, i.e: the method described above.
  • the present invention encompasses a process for preparing ODV from COBA comprising: reacting COBA and a reducing agent to obtain ODV, where optionally, PCOBA can be used as a starting material.
  • the present invention encompasses a process for preparing ODV comprising the steps of: combining OBCarboxy, a catalyst and an acid activating agent to obtain an activated acid; recovering the activated acid and combining it with an amine to obtain OBA; reacting the obtained OBA with cyclohexanone and a base able to form a carbanion; recovering the obtained COBA and reacting the obtained COBA; a reducing agent; and recovering the obtained ODV, wherein, optionally, a protected derivative of OBA (POBA) can be used as a starting material and PCOBA is obtained, which is then reacted with the reducing agent to obtain ODV.
  • POBA protected derivative of OBA
  • ambient temperature refers to a temperature of about 18° C. to about 25° C.
  • OAA hydroxyphenyl dimethylamide
  • POBA refers to protected hydroxyphenyl dimethylamide (IUPAC name: protected 2-(4-hydroxyphenyl)-N,N-dimethylacetamide) of the following structure:
  • x is a hydroxy protecting group
  • COBA refers to cyclohexyl hydroxyphenyl dimethylamide (IUPAC name 2-(1-hydroxycyclohexyl)-2-(4-hydroxyphenyl)-N,N-dimethylacetamide) of the following structure;
  • PCOBA refers to protected cyclohexyl hydroxyphenyl dimethylamide (IUPAC name: protected: 2-(1-hydroxycyclohexyl)-2-(4-hydroxyphenyl)-N,N-dimethylacetamide) of the following structure;
  • x is a hydroxy protecting group
  • ODV O-desmethylvenlafaxine
  • the present invention provides a direct synthesis of ODV via novel intermediates. This process produces ODV and its intermediates in high yields and purity.
  • ODV is synthesized without going through venlafaxine, leading to elimination of a demethylation step.
  • the intermediate OBA is condensed with cyclohexanone to form the intermediate COBA. Further, the carboxylic group of COBA is reduced, and the reduced product is converted to ODV.
  • the process can be performed via the protected intermediates POBA and PCOBA, in order to increase the yield, due to avoidance of side-reactions. The process is described in the following scheme.
  • the invention encompasses hydroxyphenyl dimethylamide (OBA) (IUPAC name 2-(4-hydroxyphenyl)-N,N-dimethylacetamide).
  • OBA hydroxyphenyl dimethylamide
  • DMSO-d6 DMSO-d6
  • 2.80 (s, CH 3 —N), 2.96 (s, CH 3 N), 3.53 (s, CH 2 ), 6.70 (m, H atom), 6.98 (m, H atom), 9.24 (s, OH).
  • the present invention provides isolated or purified OBA.
  • Isolated refers to being separated from the reaction mixture in which it forms.
  • OBA is at least about 50% pure as measured by HPLC.
  • OBA is prepared by a process comprising combining hydroxybenzyl carboxy OBCarboxy (IUPAC name: (4-hydroxyphenyl)acetic acid)) catalyst and an acid activating agent to obtain an activated acid; recovering the activated acid, and combining it with an amine to obtain OBA.
  • OBCarboxy IUPAC name: (4-hydroxyphenyl)acetic acid
  • the catalyst is an organic catalyst.
  • the catalyst is dimethyl formamide DMF or Pyridinium p-toluene sulfonate (PPTS).
  • PPTS Pyridinium p-toluene sulfonate
  • the reaction is done in the presence of a solvent.
  • the solvent is an organic solvent that does not react with the acid activating agent. More preferably, the solvent is selected from a group consisting of C 6-12 aromatic hydrocarbon, preferably C 6 to C 8 , a C 1-4 halogenated hydrocarbon, preferably chloroform, dichloromethane, a C 4-8 ether preferably C 4 to C 6 ether, more preferably tetrahydrofuran, diethylether, methyltert-butyl ether and mixtures thereof. Even more preferably, the solvent is selected from a group consisting of toluene, CH 2 Cl 2 and THF. Most preferably, the solvent is CH 2 Cl 2 .
  • the reaction with the acid activating agent is exothermic; hence the mixture is cooled prior to combining it with the acid activating agent.
  • the mixture is cooled to a temperature of about ⁇ 10° C. to about 10° C., preferably ⁇ 5° C. to about 5° C., more preferably, to a temperature of about 0° C.
  • the acid activating agent is added dropwise, preferably during 30 minutes to about 3 hours.
  • the acid activating agent is an agent that activates carboxylic acids, i.e., converts the “OH” to a suitable leaving group.
  • the activating agent may be SOCl 2 , COCl 2 , DCC (N′-dicyclohexyl carbodiimide) or analogs, HOBT (N-Hydroxybenzotriazole), FMOC (fluorenylmethoxycarbonyl) or analogs (and other analogs used in peptide chemistry) or PC15 or (COCl) 2 .
  • the activating agent is SOCl 2 .
  • the obtained mixture is heated, preferably to a temperature of about 0° C. to about 30° C., preferably about 15° C. to about 28°. More preferably the heating is to a temperature of about ambient temperature.
  • the heated mixture is stirred for a sufficient time to obtain the activated acid, preferably for a period of time of about 0.5 to about 3 hours, preferably for about 1 to about 2.5 hours. More preferably, the stirring is for about 2 hours.
  • the activated acid is optionally recovered by any method known in the art. Preferably, it is recovered by removing the solvent and providing a residue comprising of the activated acid.
  • One of ordinary skill of art can also devise a one pot process which skips recovery of the intermediate in the synthetic scheme.
  • the solvent is removed by evaporation under reduced pressure (pressure of below one atmosphere).
  • the residue is optionally dissolved in another organic solvent; wherein the solvent is described above.
  • the solution is combined with dimethylamine to provide a mixture.
  • the amine salt is dimethylamine-HCl and the second amine is a C 3 -C 9 trialkylamine, where each alkyl chain is independently selected from C 1 -C 7 carbons.
  • Example of such amine includes diisopropylethylamine.
  • a gaseous amine can also be used.
  • the second amine is added dropwise, more preferably, during about 1 hour.
  • the mixture is then stirred for a sufficient time to obtain OBA.
  • the stirring is done over a period of time of about 1 hour to about 24 hours more preferably about 4 hours to about 16 hours. More preferably, the stirring is performed overnight.
  • OBA can be recovered.
  • the recovery is preferably done by quenching the new mixture providing a precipitate; washing, filtering, and drying.
  • the quenching is done by adding a saturated solution of a base.
  • the base is an inorganic base, such as an alkali metal or alkaline earth metal carbonate/bicarbonate.
  • the base is NaHCO 3 .
  • the precipitate is filtered under a reduced pressure.
  • the washing is done with methylene chloride, and the drying, under vacuum (pressure of less than about 100 mmHg).
  • the drying is at a temperature of about 20° C. to about 80° C. More preferably, the drying is done at room temperature.
  • the process for preparing OBA can further comprise a process for converting OBA to ODV.
  • OBA can be transformed to ODV via another intermediated such as COBA.
  • the present invention encompasses hydroxy protected OBA (POBA).
  • POBA hydroxy protected OBA
  • Suitable hydroxy protected groups are listed in T. W. Greene, Protective Groups in Organic Synthesis, (2 nd ed.), which is incorporated herein by reference.
  • POBA is a silyl-protected POBA, such as a tri(C 1-6 alkyl)silyl-protected POBA, wherein the alkyl groups can be the same or different, preferably t-butyldimethylsilyl ether (TBDMS)-protected OBA, or trimethylsilyl (TMS), with TBDMS being preferred, or DHP-protected OBA.
  • TDMS t-butyldimethylsilyl ether
  • TMS trimethylsilyl
  • the present invention provides isolated or purified POBA, including TBDMS-OBA.
  • Isolated refers to being separated from the reaction mixture in which it forms.
  • the POBA is at least about 50% pure as measured by HPLC.
  • TBDMS-OBA is characterized by 1 HNMR (Bruker DPX-300 (DMSO-d6)) with ⁇ : 0.20 (s, Me2Si), 0.99 (s, tBuSi), 2.85 (s, CH 3 —N), 2.99 (s, CH 3 N), 3.62 (s, CH 2 ), 6.77 (m, H atom), 7.10 (m, H atom).
  • POBA including TBDMS-OBA
  • TBDMS-OBA can be prepared by combining OBA with a suitable hydroxyl protecting agent and a base.
  • An acid may also be used instead of a base.
  • the reaction is done in the presence of a solvent.
  • the solvent is an organic solvent.
  • the solvent is a non-protic solvent.
  • the organic solvent can be a C 6 to C 12 aromatic hydrocarbon or a C 1 -C 6 chlorinated hydrocarbon or C 4-6 ether. More preferably, the solvent is selected from the group consisting of toluene, CH 2 Cl 2 and THF. Most preferably, the solvent is CH 2 Cl 2 .
  • the hydroxyl protecting agent is a trialkylsilyl halide, preferably a tri(C 1-6 alkyl)silyl halide, wherein the alkyl may be the same or different, preferably the trialkylsilyl halide is a trimethylsilyl halide or a tert-butyldimethylsilyl halide, wherein the halide is chloride or bromide or DHP (dihydropyran).
  • the hydroxyl protecting agent is a silyl protecting group or DHP (dihydropyran). More preferably, the hydroxyl protecting agent is TBDMS-Cl, acetylchloride or acetic anhydride.
  • the base is imidazole.
  • Other bases such as pyridine, triethylamine, lutidine, dimethylaminopyridine may also be used.
  • the obtained combination is stirred at a temperature of about 0° C. to about 100° C., preferably about 40° C. to about 70° C. Preferably, the stirring is done at a temperature of about 55° C.
  • the above combination is maintained, while stirring, for about 0.5 hour to about 24 hours, preferably about 1 hour to about 4 hours, more preferably for about two hours, during which POBA is formed.
  • the process for preparing POBA can further comprise a recovery process.
  • the recovery is, preferably done by quenching the combination providing a two-phase system; separating the obtained two phases, washing and drying the organic phase, followed by filtering and solvent evaporation under reduced pressure (pressure of less than one atmosphere).
  • the combination is quenched with brine and 10% aqueous solution of citric acid.
  • the process for preparing POBA can further comprise a process for converting POBA to ODV.
  • POBA can be converted to ODV via COBA or PCOBA.
  • the present invention encompasses cyclohexylOBA (COBA).
  • COBA cyclohexylOBA
  • isolated or purified COBA refers to being separated from the reaction mixture in which it forms.
  • the COBA is at least about 50% pure as measured by HPLC.
  • COBA can be prepared by reacting OBA with cyclohexanone and a base able to form a carbanion; and recovering the obtained COBA.
  • a protected derivative of OBA can be used as a starting material, to obtain PCOBA.
  • the reaction is done in the presence of a solvent.
  • the solvent is as described above. More preferably, the solvent is THF.
  • OBA or POBA is combined with the solvent to obtain a mixture.
  • a base able to form a carbanion is added, providing a new mixture.
  • the base is able to form a carbanion. More preferably, the base is LDA; or alkali metal or alkaline earth metal (such as lithium) diisopropylamide; or BuLi.
  • the base may also be Sodium hydride (NaH); or alkali metal or alkaline earth metal (such as sodium or potassium or lithium) salts of bis trimethylsilylamide ⁇ MN(SiMe 3 ) 2 ⁇ ; or metal salt of tert-butoxide (MOtBu)
  • the reaction of the base with the reagent is exothermic.
  • the base is added at a temperature of about 80° C. to about 25° C.
  • the addition can be done at ambient temperature, and when the base is BuLi, the addition can be done at a temperature of about ⁇ 80° C.
  • the base is added dropwise.
  • the dropwise addition is done during a period of time of about 30 minutes.
  • the new mixture is then stirred.
  • the stirring is for about 10 minutes to about 2 hours. More preferably, the new mixture is stirred for about 30 minutes.
  • Cyclohexanone is then added to the mixture.
  • cyclohexanone is added dropwise, more preferably, during a period of time of 30 minutes.
  • the obtained mixture is maintained, while being stirred, for about 30 minutes to about 24 hours, more preferably, the stirring is done overnight.
  • the reaction mixture can then be quenched, by reacting the reaction mixture with a proton donor, such as NH 4 Cl.
  • a proton donor such as NH 4 Cl.
  • the recovery provides COBA or PCOBA, depending on the starting material.
  • the recovery stage includes: separating the layers obtained after quenching, washing the organic layer obtained after quenching with brine, and further evaporating the residual organic solvent under reduced pressure (pressure of less than one atmosphere) to obtain COBA or PCOBA.
  • the present invention encompasses a hydroxyl protected cyclohexylOBA (PCOBA).
  • PCOBA is TBDMS-protected COBA.
  • the process for preparing COBA or PCOBA can further comprise a process for converting COBA or PCOBA to ODV.
  • COBA and PCOBA can be converted to ODV by reacting COBA or PCOBA with a reducing agent, and recovering to obtain ODV.
  • COBA or PCOBA are combined with a solvent to obtain a solution.
  • Solvents that are inert to the reducing agent can be used.
  • the solvent is THF.
  • a reducing agent is added, preferably, the reducing agent is a metal hydride complex.
  • the metal hydride complex is selected from a group consisting of BH 3 derivatives or aluminum hydride derivatives.
  • the reducing agent is LiAlH 4 , NaBH 4 , NaBH3CN: sodium cyanoborohydride
  • the hydrogenation may be performed under H 2 pressure in presence of catalyst such Ni or Co.
  • the reducing agent is added dropwise to avoid heat accumulation.
  • the addition can be done during a period of time of about 30 min.
  • the addition can preferably be done at a temperature of about ⁇ 50° C. to about RT.
  • the temperature is ambient temperature.
  • the addition of the reducing agent provides a mixture.
  • the mixture is stirred for about 1 hour to about 24 hours. More preferably, the stirring is stirred for over night.
  • the recovery of ODV is done by quenching. More preferably the quenching is done by acidification of the mixture. Acidification is done for example by adding aqueous solution of HCl or NH 4 Cl.
  • the quenching typically, provides a two-phase system, comprising of an aqueous phase and of an organic phase. The phases are separated, and the aqueous phase is neutralized preferably, by adding a base.
  • the neutralization is done by adding a base such as an alkali or alkaline earth metal carbonate/bicarbonate.
  • the base is a saturated solution of NaHCO 3 .
  • the process for preparing ODV can further comprise a recovery process.
  • the recovery can be done by extracting ODV from the aqueous layer, such as by adding a water immiscible organic solvent.
  • the water immiscible organic solvent is CH 2 Cl 2 , EtOAc, hexanes or toluene
  • the extract may then be dried, filtered and evaporated under reduced pressure (pressure of less than one atmosphere).
  • the drying is preferably over Na 2 SO 4 .
  • ODV can be synthesized by combining OBCarboxy, a catalyst and an acid activating agent to obtain an activated acid; recovering the activated acid, combining it with an amine to obtain OBA; reacting the obtained OBA with cyclohexanone and a base able to form a carbanion; recovering the obtained COBA; reacting the obtained COBA, and a reducing agent; and recovering the obtained ODV.
  • a protected derivative of OBA can be used as a starting material for the process for preparing PCOBA, and wherein, optionally, a protected derivative of COBA (PCOBA) can be used as a starting material for the preparation of ODV.
  • POBA protected derivative of OBA
  • PCOBA protected derivative of COBA
  • OBA (1.45 g, 8.09 mmol) was dissolved at room temperature in DHP (8 ml) under nitrogen.
  • Pyridinium p-toluene sulfonate PPTS, catalytic amount
  • PPTS Pyridinium p-toluene sulfonate
  • the reaction was monitored by HPLC.
  • EtOAc was added and the organic layer was washed with brine, dried over MgSO 4 and filtered under reduced pressure to get OBA-DHP.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)

Abstract

Provided are processes and intermediates for the synthesis of O-desmethylvenlafaxine.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • The present application claims the benefit of the following U.S. Provisional Patent Application Nos. 60/833,616, filed Jul. 26, 2006; 60/837,879, filed Aug. 14, 2006; 60/849,216, filed Oct. 3, 2006; 60/843,998, filed Sep. 11, 2006; 60/849,255, filed Oct. 3, 2006; 60/906,639, filed Mar. 12, 2007; and 60/906,879, filed Mar. 13, 2007. The contents of these applications are incorporated herein by reference.
  • FIELD OF THE INVENTION
  • The invention encompasses a process for the synthesis of O-desmethylvenlafaxine.
  • BACKGROUND OF THE INVENTION
  • Venlafaxine, (±)-1-[2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol, of the following formula,
  • Figure US20080183016A1-20080731-C00001
  • is the first of a class of anti-depressants. Venlafaxine acts by inhibiting re-uptake of norepinephrine and serotonin, and is an alternative to the tricyclic anti-depressants and selective re-uptake inhibitors.
  • O-desmethylvenlafaxine, 4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol, of the following formula,
  • Figure US20080183016A1-20080731-C00002
  • is reported to be a metabolite of venlafaxine, which is known also as an inhibitor of norepiniphrine and serotonin uptake, See Klamerus, K. J. et al., “Introduction of the Composite Parameter to the Pharmacokinetics of Venlafaxine and its Active O-Desmethyl Metabolite,” and J. Clin. Pharmacol. 32:716-724 (1992).
  • Processes for the synthesis of O-desmethylvenlafaxine by demethylation of the methoxy group of venlafaxine are described in U.S. Pat. Nos. 7,026,508 and in 6,689,912.
  • The synthesis disclosed in the above patents is performed according to the following scheme:
  • Figure US20080183016A1-20080731-C00003
  • wherein “MBC” refers to methyl benzyl cyanide, “CMBC” refers to cyclohexyl methylbenzyl cyanide, “DDMV” refers to didesmethyl venlafaxine, and “ODV” refers to O-desmethylvenlafaxine.
  • The demethylation process disclosed in U.S. Pat. No. 7,026,508 provides ODV succinate salt by using L-selectride, which is an alkali metal salt of trialkyl borohydride; where hydrogen gas is formed during the reaction. Hence, the process isn't suitable for industrial scale manufacture.
  • US application No. 2005/0197392 describes a method for preparing (±)O-desmethylvenlafaxine hydrochloride salt by reacting venlafaxine with lithium diphenyl phosphide.
  • U.S. Pat. No. 6,689,912 describes demethylation process performed by using a salt of high molecular weight alkane, arene, or arylalkyl thiolate anion in the presence of protic or aprotic solvent. The salt can be prepared separately and then react with venlafaxine, or can react in-situ with venlafaxine. When prepared separately, the solvent, methanol should be removed. This operation is very complicated because the mixture containing the salt is highly viscous, hence the operation necessitate long time even under high vacuum. When the reaction is performed in-situ via removal of methanol in situ, this operation is still tedious and only partially successful, since it is difficult to reach the high temperature that the reaction necessitate to advance.
  • The described ODV synthesis processes are all indirect, i.e; performed via Venlafaxine. The present invention provides a direct synthesis of O-desmethylvenlafaxine; i.e.; without passing through venlafaxine as an intermediate.
  • SUMMARY OF THE INVENTION
  • In one embodiment, the invention encompasses hydroxyphenyl dimethylamide (OBA), having the following formula,
  • Figure US20080183016A1-20080731-C00004
  • In another embodiment, the present invention provides a process for preparing hydroxyphenyl dimethylamide (OBA) comprising combining hydroxybenzyl carboxy (OBCarboxy), a catalyst and an acid activating agent to obtain an activated acid; recovering the activated acid, and combining it with a dimethylamine to obtain OBA.
  • Preferably, the process for preparing OBA is done in the presence of an organic solvent.
  • In yet another embodiment, the present invention provides a process for preparing ODV by preparing OBA as described above, and converting it to ODV. OBA can be transformed to ODV via another intermediated such as COBA.
  • In yet another embodiment, the present invention encompasses hydroxy protected OBA (POBA), having the following formula,
  • Figure US20080183016A1-20080731-C00005
  • In another embodiment, the present invention encompasses a process for preparing POBA comprising; combining OBA with a hydroxyl protecting agent and a base.
  • In yet another embodiment, the present invention provides a process for preparing ODV by preparing POBA as described above, and converting it to ODV. POBA can be transformed to ODV via another intermediated such as PCOBA.
  • In yet another embodiment, the present invention encompasses cyclohexylOBA (COBA), having the following formula,
  • Figure US20080183016A1-20080731-C00006
  • In one embodiment the process for the preparation of cyclohexylOBA (COBA) comprising: reacting OBA with cyclohexanone and a base able to form a carbanion; and recovering the obtained COBA.
  • In yet another embodiment, the present invention provides a process for preparing ODV by preparing COBA as described above, and converting it to ODV, by any method known in the art, i.e: the method described above.
  • In yet another embodiment, the present invention encompasses a hydroxyl protected COBA (PCOBA), having the following formula,
  • Figure US20080183016A1-20080731-C00007
  • PCOBA
  • In another embodiment the process for preparing PCOBA comprising; combining POBA with cyclohexanone and a base able to form a carbanion; and recovering the obtained PCOBA.
  • In yet another embodiment, the present invention provides a process for preparing ODV by preparing PCOBA as described above and converting it to ODV, by any method known in the art, i.e: the method described above.
  • In another embodiment, the present invention encompasses a process for preparing ODV from COBA comprising: reacting COBA and a reducing agent to obtain ODV, where optionally, PCOBA can be used as a starting material.
  • In another embodiment, the present invention encompasses a process for preparing ODV comprising the steps of: combining OBCarboxy, a catalyst and an acid activating agent to obtain an activated acid; recovering the activated acid and combining it with an amine to obtain OBA; reacting the obtained OBA with cyclohexanone and a base able to form a carbanion; recovering the obtained COBA and reacting the obtained COBA; a reducing agent; and recovering the obtained ODV, wherein, optionally, a protected derivative of OBA (POBA) can be used as a starting material and PCOBA is obtained, which is then reacted with the reducing agent to obtain ODV.
  • DETAILED DESCRIPTION OF THE INVENTION
  • As used herein, the term “ambient temperature” refers to a temperature of about 18° C. to about 25° C.
  • As used herein, the term “OBA” refers to hydroxyphenyl dimethylamide (IUPAC name 2-(4-hydroxyphenyl)-N,N-dimethylacetamide) of the following structure:
  • Figure US20080183016A1-20080731-C00008
  • As used herein, the term “POBA” refers to protected hydroxyphenyl dimethylamide (IUPAC name: protected 2-(4-hydroxyphenyl)-N,N-dimethylacetamide) of the following structure:
  • Figure US20080183016A1-20080731-C00009
  • wherein x is a hydroxy protecting group.
  • As used herein, the term “COBA” refers to cyclohexyl hydroxyphenyl dimethylamide (IUPAC name 2-(1-hydroxycyclohexyl)-2-(4-hydroxyphenyl)-N,N-dimethylacetamide) of the following structure;
  • Figure US20080183016A1-20080731-C00010
  • As used herein, the term “PCOBA” refers to protected cyclohexyl hydroxyphenyl dimethylamide (IUPAC name: protected: 2-(1-hydroxycyclohexyl)-2-(4-hydroxyphenyl)-N,N-dimethylacetamide) of the following structure;
  • Figure US20080183016A1-20080731-C00011
  • wherein x is a hydroxy protecting group.
  • As used herein, the term “ODV” refers to O-desmethylvenlafaxine.
  • The present invention provides a direct synthesis of ODV via novel intermediates. This process produces ODV and its intermediates in high yields and purity. In the process of the present invention ODV is synthesized without going through venlafaxine, leading to elimination of a demethylation step.
  • In the process of the invention, the intermediate OBA is condensed with cyclohexanone to form the intermediate COBA. Further, the carboxylic group of COBA is reduced, and the reduced product is converted to ODV. The process can be performed via the protected intermediates POBA and PCOBA, in order to increase the yield, due to avoidance of side-reactions. The process is described in the following scheme.
  • Figure US20080183016A1-20080731-C00012
  • In one embodiment, the invention encompasses hydroxyphenyl dimethylamide (OBA) (IUPAC name 2-(4-hydroxyphenyl)-N,N-dimethylacetamide). OBA is characterized by 1HNMR (Bruker DPX-300 (DMSO-d6)) with δ: 2.80 (s, CH3—N), 2.96 (s, CH3N), 3.53 (s, CH2), 6.70 (m, H atom), 6.98 (m, H atom), 9.24 (s, OH). OBA has a mass of 180 (MS (CI+)=180).
  • In one embodiment the present invention provides isolated or purified OBA. Isolated refers to being separated from the reaction mixture in which it forms. Preferably the OBA is at least about 50% pure as measured by HPLC.
  • OBA is prepared by a process comprising combining hydroxybenzyl carboxy OBCarboxy (IUPAC name: (4-hydroxyphenyl)acetic acid)) catalyst and an acid activating agent to obtain an activated acid; recovering the activated acid, and combining it with an amine to obtain OBA.
  • Preferably, the catalyst is an organic catalyst. Most preferably, the catalyst is dimethyl formamide DMF or Pyridinium p-toluene sulfonate (PPTS). Typically, the reaction is done in the presence of a solvent. The solvent is an organic solvent that does not react with the acid activating agent. More preferably, the solvent is selected from a group consisting of C6-12 aromatic hydrocarbon, preferably C6 to C8, a C1-4 halogenated hydrocarbon, preferably chloroform, dichloromethane, a C4-8 ether preferably C4 to C6 ether, more preferably tetrahydrofuran, diethylether, methyltert-butyl ether and mixtures thereof. Even more preferably, the solvent is selected from a group consisting of toluene, CH2Cl2 and THF. Most preferably, the solvent is CH2Cl2.
  • Usually, the reaction with the acid activating agent is exothermic; hence the mixture is cooled prior to combining it with the acid activating agent. Preferably, the mixture is cooled to a temperature of about −10° C. to about 10° C., preferably −5° C. to about 5° C., more preferably, to a temperature of about 0° C.
  • In order to decrease the exothermic effect of the reaction, the acid activating agent is added dropwise, preferably during 30 minutes to about 3 hours. Preferably, the acid activating agent is an agent that activates carboxylic acids, i.e., converts the “OH” to a suitable leaving group. The activating agent may be SOCl2, COCl2, DCC (N′-dicyclohexyl carbodiimide) or analogs, HOBT (N-Hydroxybenzotriazole), FMOC (fluorenylmethoxycarbonyl) or analogs (and other analogs used in peptide chemistry) or PC15 or (COCl)2. Most preferably, the activating agent is SOCl2.
  • Following to the addition of the activating agent, the obtained mixture is heated, preferably to a temperature of about 0° C. to about 30° C., preferably about 15° C. to about 28°. More preferably the heating is to a temperature of about ambient temperature.
  • The heated mixture is stirred for a sufficient time to obtain the activated acid, preferably for a period of time of about 0.5 to about 3 hours, preferably for about 1 to about 2.5 hours. More preferably, the stirring is for about 2 hours.
  • The activated acid is optionally recovered by any method known in the art. Preferably, it is recovered by removing the solvent and providing a residue comprising of the activated acid. One of ordinary skill of art can also devise a one pot process which skips recovery of the intermediate in the synthetic scheme.
  • Preferably the solvent is removed by evaporation under reduced pressure (pressure of below one atmosphere).
  • Then, the residue is optionally dissolved in another organic solvent; wherein the solvent is described above. Subsequently, the solution is combined with dimethylamine to provide a mixture. This reaction is more facile if a dimethylamine salt is used, and then the salt is removed with another amine. Preferably the amine salt is dimethylamine-HCl and the second amine is a C3-C9 trialkylamine, where each alkyl chain is independently selected from C1-C7 carbons. Example of such amine includes diisopropylethylamine. A gaseous amine can also be used. Preferably, the second amine is added dropwise, more preferably, during about 1 hour.
  • The mixture is then stirred for a sufficient time to obtain OBA. Preferably, the stirring is done over a period of time of about 1 hour to about 24 hours more preferably about 4 hours to about 16 hours. More preferably, the stirring is performed overnight.
  • OBA can be recovered. The recovery is preferably done by quenching the new mixture providing a precipitate; washing, filtering, and drying. Preferably, the quenching is done by adding a saturated solution of a base. More preferably, the base is an inorganic base, such as an alkali metal or alkaline earth metal carbonate/bicarbonate. Most preferably, the base is NaHCO3.
  • Preferably, the precipitate is filtered under a reduced pressure. Preferably, the washing is done with methylene chloride, and the drying, under vacuum (pressure of less than about 100 mmHg). Preferably, the drying is at a temperature of about 20° C. to about 80° C. More preferably, the drying is done at room temperature.
  • The process for preparing OBA can further comprise a process for converting OBA to ODV. OBA can be transformed to ODV via another intermediated such as COBA.
  • In another embodiment, the present invention encompasses hydroxy protected OBA (POBA). Suitable hydroxy protected groups are listed in T. W. Greene, Protective Groups in Organic Synthesis, (2nd ed.), which is incorporated herein by reference. Most preferably, POBA is a silyl-protected POBA, such as a tri(C1-6 alkyl)silyl-protected POBA, wherein the alkyl groups can be the same or different, preferably t-butyldimethylsilyl ether (TBDMS)-protected OBA, or trimethylsilyl (TMS), with TBDMS being preferred, or DHP-protected OBA.
  • In one embodiment the present invention provides isolated or purified POBA, including TBDMS-OBA. Isolated refers to being separated from the reaction mixture in which it forms. Preferably the POBA is at least about 50% pure as measured by HPLC.
  • TBDMS-OBA is characterized by 1HNMR (Bruker DPX-300 (DMSO-d6)) with δ: 0.20 (s, Me2Si), 0.99 (s, tBuSi), 2.85 (s, CH3—N), 2.99 (s, CH3N), 3.62 (s, CH2), 6.77 (m, H atom), 7.10 (m, H atom).
  • POBA, including TBDMS-OBA, can be prepared by combining OBA with a suitable hydroxyl protecting agent and a base. An acid may also be used instead of a base.
  • Usually, the reaction is done in the presence of a solvent. Preferably, the solvent is an organic solvent. Preferably the solvent is a non-protic solvent. The organic solvent can be a C6 to C12 aromatic hydrocarbon or a C1-C6 chlorinated hydrocarbon or C4-6 ether. More preferably, the solvent is selected from the group consisting of toluene, CH2Cl2 and THF. Most preferably, the solvent is CH2Cl2.
  • Preferably, the hydroxyl protecting agent is a trialkylsilyl halide, preferably a tri(C1-6 alkyl)silyl halide, wherein the alkyl may be the same or different, preferably the trialkylsilyl halide is a trimethylsilyl halide or a tert-butyldimethylsilyl halide, wherein the halide is chloride or bromide or DHP (dihydropyran). Preferably, the hydroxyl protecting agent is a silyl protecting group or DHP (dihydropyran). More preferably, the hydroxyl protecting agent is TBDMS-Cl, acetylchloride or acetic anhydride.
  • Preferably, the base is imidazole. Other bases such as pyridine, triethylamine, lutidine, dimethylaminopyridine may also be used.
  • The obtained combination is stirred at a temperature of about 0° C. to about 100° C., preferably about 40° C. to about 70° C. Preferably, the stirring is done at a temperature of about 55° C.
  • Preferably the above combination is maintained, while stirring, for about 0.5 hour to about 24 hours, preferably about 1 hour to about 4 hours, more preferably for about two hours, during which POBA is formed.
  • The process for preparing POBA can further comprise a recovery process. The recovery is, preferably done by quenching the combination providing a two-phase system; separating the obtained two phases, washing and drying the organic phase, followed by filtering and solvent evaporation under reduced pressure (pressure of less than one atmosphere). Preferably, the combination is quenched with brine and 10% aqueous solution of citric acid.
  • The process for preparing POBA can further comprise a process for converting POBA to ODV. POBA can be converted to ODV via COBA or PCOBA.
  • In another embodiment, the present invention encompasses cyclohexylOBA (COBA). Also provided is isolated or purified COBA. Isolated refers to being separated from the reaction mixture in which it forms. Preferably the COBA is at least about 50% pure as measured by HPLC.
  • COBA can be prepared by reacting OBA with cyclohexanone and a base able to form a carbanion; and recovering the obtained COBA. Optionally, a protected derivative of OBA can be used as a starting material, to obtain PCOBA.
  • Usually, the reaction is done in the presence of a solvent. Preferably, the solvent is as described above. More preferably, the solvent is THF.
  • Initially, OBA or POBA is combined with the solvent to obtain a mixture. Then a base able to form a carbanion is added, providing a new mixture.
  • Preferably, the base is able to form a carbanion. More preferably, the base is LDA; or alkali metal or alkaline earth metal (such as lithium) diisopropylamide; or BuLi. The base may also be Sodium hydride (NaH); or alkali metal or alkaline earth metal (such as sodium or potassium or lithium) salts of bis trimethylsilylamide {MN(SiMe3)2}; or metal salt of tert-butoxide (MOtBu)
  • The reaction of the base with the reagent is exothermic. Preferably, the base is added at a temperature of about 80° C. to about 25° C. For example, when the base is LDA, the addition can be done at ambient temperature, and when the base is BuLi, the addition can be done at a temperature of about −80° C.
  • Usually, the base is added dropwise. Preferably, the dropwise addition is done during a period of time of about 30 minutes. The new mixture is then stirred. Preferably, the stirring is for about 10 minutes to about 2 hours. More preferably, the new mixture is stirred for about 30 minutes.
  • Cyclohexanone is then added to the mixture. Preferably cyclohexanone is added dropwise, more preferably, during a period of time of 30 minutes.
  • Preferably, the obtained mixture is maintained, while being stirred, for about 30 minutes to about 24 hours, more preferably, the stirring is done overnight.
  • The reaction mixture can then be quenched, by reacting the reaction mixture with a proton donor, such as NH4Cl. The recovery provides COBA or PCOBA, depending on the starting material.
  • PCOBA and COBA can then be recovered. Preferably, the recovery stage includes: separating the layers obtained after quenching, washing the organic layer obtained after quenching with brine, and further evaporating the residual organic solvent under reduced pressure (pressure of less than one atmosphere) to obtain COBA or PCOBA.
  • In another embodiment, the present invention encompasses a hydroxyl protected cyclohexylOBA (PCOBA). Preferably, PCOBA is TBDMS-protected COBA.
  • The process for preparing COBA or PCOBA can further comprise a process for converting COBA or PCOBA to ODV. COBA and PCOBA can be converted to ODV by reacting COBA or PCOBA with a reducing agent, and recovering to obtain ODV.
  • Usually, COBA or PCOBA are combined with a solvent to obtain a solution. Solvents that are inert to the reducing agent can be used. Preferably the solvent is THF. Subsequently, a reducing agent is added, preferably, the reducing agent is a metal hydride complex. More preferably, the metal hydride complex is selected from a group consisting of BH3 derivatives or aluminum hydride derivatives. Most preferably, the reducing agent is LiAlH4, NaBH4, NaBH3CN: sodium cyanoborohydride Instead of using metal hydride complex, the hydrogenation may be performed under H2 pressure in presence of catalyst such Ni or Co.
  • Usually, the reducing agent is added dropwise to avoid heat accumulation. The addition can be done during a period of time of about 30 min. The addition can preferably be done at a temperature of about −50° C. to about RT. Preferably, the temperature is ambient temperature.
  • The addition of the reducing agent provides a mixture. Preferably, the mixture is stirred for about 1 hour to about 24 hours. More preferably, the stirring is stirred for over night.
  • Preferably, the recovery of ODV is done by quenching. More preferably the quenching is done by acidification of the mixture. Acidification is done for example by adding aqueous solution of HCl or NH4Cl. The quenching, typically, provides a two-phase system, comprising of an aqueous phase and of an organic phase. The phases are separated, and the aqueous phase is neutralized preferably, by adding a base. The neutralization is done by adding a base such as an alkali or alkaline earth metal carbonate/bicarbonate. Preferably, the base is a saturated solution of NaHCO3.
  • The process for preparing ODV can further comprise a recovery process. The recovery can be done by extracting ODV from the aqueous layer, such as by adding a water immiscible organic solvent. Preferably, the water immiscible organic solvent is CH2Cl2, EtOAc, hexanes or toluene
  • The extract may then be dried, filtered and evaporated under reduced pressure (pressure of less than one atmosphere). The drying is preferably over Na2SO4.
  • One of ordinary skill of art would appreciate that each above described process can be combined into one continuous process for synthesis of ODV. In such process ODV can be synthesized by combining OBCarboxy, a catalyst and an acid activating agent to obtain an activated acid; recovering the activated acid, combining it with an amine to obtain OBA; reacting the obtained OBA with cyclohexanone and a base able to form a carbanion; recovering the obtained COBA; reacting the obtained COBA, and a reducing agent; and recovering the obtained ODV. Optionally, a protected derivative of OBA (POBA) can be used as a starting material for the process for preparing PCOBA, and wherein, optionally, a protected derivative of COBA (PCOBA) can be used as a starting material for the preparation of ODV.
  • Having described the invention with reference to certain preferred embodiments, other embodiments will become apparent to one skilled in the art from consideration of the specification. The invention is further defined by reference to the following examples describing in detail the synthesis of the compound OBA, COBA, their protected forms and further their conversion to O-desmethylvenlafaxine. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of the invention.
  • EXAMPLES Preparation of OBA Example 1
  • A 500 ml three-neck flask equipped with nitrogen inlet, thermometer and mechanical stirrer was charged with OBcarboxy (10 g, 65.72 mmol), DMF (1 ml) and CH2Cl2 (50 ml). The reaction mixture was stirred at 0° C. and SOCl2 was added dropwise.
  • The reaction was stirred at ambient temperature for 2 hours and then the solvent was evaporated under reduced pressure. The residue was dissolved in CH2Cl2 (50 ml) and dimethylamine-HCl (100 g, 1.22 mol) was added. Then diisopropylethylamine (150 ml, 0.882 mol) was added dropwise. The mixture was stirred at ambient temperature overnight and then washed with a saturated solution of NaHCO3; a precipitate appeared. The precipitate was filtered under reduced pressure and washed with methylene chloride. The solid so-obtained was dried in a vacuum oven at room temperature to get 5.55 g of OBA (purity 99.45%).
  • The organic layer was washed with brine and evaporated to dryness yielding crystals 5.84 g OBA (purity 96.57%). Total yield=97.85%.
  • Preparation of Protected OBA (POBA) Example 2
  • A 100 ml three-neck flask equipped with nitrogen inlet, thermometer and mechanical stirrer was charged with OBA (2.4 g, 13.39 mmol) TBDMS-Cl (4.5 g, 29.9 mmol), imidazole (5.5 g, 80.78 mmol) and CH2Cl2 (20 ml). The reaction mixture was stirred at ambient temperature for 2 hours. The reaction was quenched with brine and a 10% aqueous solution of citric acid The organic phase was then washed with brine and dried over Na2SO4. After filtration the solvent was evaporated under reduced pressure to get 3.82 g OBA-P (purity: 99.34%, yield: 97.45%).
  • Example 3
  • In a 50 ml flask equipped with a mechanical stirrer, OBA (1.45 g, 8.09 mmol) was dissolved at room temperature in DHP (8 ml) under nitrogen. Pyridinium p-toluene sulfonate (PPTS, catalytic amount) was added and the reaction mixture was heated to 55° C. for 5 hours. The reaction was monitored by HPLC. EtOAc was added and the organic layer was washed with brine, dried over MgSO4 and filtered under reduced pressure to get OBA-DHP.
  • Preparation of Protected COBA (PCOBA) Example 4
  • A 100 ml three-neck flask equipped with nitrogen inlet, thermometer and mechanical stirrer was charged with OBA-TBDMS (3.8 g 12.95 mmol) and THF (50 ml). The solution was cooled to −80° C. and n-BuLi (1M in Hexane 8.5 ml 13.6 mmol) was added dropwise. The reaction was stirred at −80° C. for 45 min and cyclohexanone (1.7 g, 17.32 mmol) was added dropwise. This mixture was stirred for 3 hours at this temperature and poured into a saturated solution of NH4Cl. The layers were separated.
  • The organic layer was washed with brine and dried over Na2SO4. After filtration the solvent was evaporated under reduced pressure to get 4.85 g of COBA-P (purity: 79.63%, yield: 95.65%)
  • Preparation of COBA Via OBA Example 5
  • A 100 ml three-neck flask equipped with nitrogen inlet, thermometer and mechanical stirrer was charged with OBA (1.2 g, 6.69 mmol) and THF (10 ml). The mixture was stirred at ambient temperature and LDA (2M in THF 7 ml, 14.02 mmol) was added dropwise. The mixture was stirred at this temperature for 30 min and cyclohexanone (1.4 g, 14.26 mmol) was added dropwise. This mixture was stirred overnight at ambient temperature and then poured into a NH4Cl aqueous saturated solution. The layers were separated and the organic phase was washed with brine dried over Na2SO4 and evaporated under reduced pressure to get COBA.
  • Preparation of ODV Via PCOBA Example 6
  • A 100 ml three-neck flask equipped with nitrogen inlet, thermometer and mechanical stirrer was charged with PCOBA-TBDMS (2.2 g, 5.6 mmol) and THF (30 ml). This solution was stirred at ambient temperature and LiAlH4 (1M in THF10 ml, 10 mmol) was added dropwise. The mixture was stirred at ambient temperature overnight. This mixture was then acidified with a 10% aqueous solution of HCl. The layers were separated and the aqueous phase was basified with a NaHCO3 saturated solution. The aqueous layer was extracted with CH2Cl2, dried over Na2SO4, filtered and evaporated under reduced pressure to get 0.43 g of ODV (purity=100%).
  • Preparation of ODV Via COBA Example 7
  • A 100 ml three-neck flask equipped with nitrogen inlet, thermometer and mechanical stirrer is charged with COBA-TBDMS (2.2 g, 5.6 mmol) and THF (30 ml). This solution is stirred at ambient temperature and LiAlH4 (1M in THF10 ml, 10 mmol) is added dropwise. The mixture is stirred at ambient temperature overnight. This mixture is then acidified with a 10% aqueous solution of HCl. The layers are separated and the aqueous phase is basified with a NaHCO3 saturated solution. The aqueous layer is extracted with CH2Cl2, dried over Na2SO4, filtered and evaporated under reduced pressure to obtain ODV.

Claims (39)

1. 2-(4-hydroxyphenyl)-N,N-dimethylacetamide having the structure:
Figure US20080183016A1-20080731-C00013
2-3. (canceled)
4. A process for preparing the 2-(4-hydroxyphenyl)-N,N-dimethylacetamide of claim 1 comprising forming an acid-activated derivative of 4-hydroxyphenylacetic acid (4-hydroxyphenyl)acetic acid), and reacting the activated acid with dimethylamine.
5. A process according to claim 4 wherein the acid-activated derivative of 4-hydroxyphenylacetic acid is prepared by combining 4-hydroxyphenylacetic acid with an acid activating agent and a catalyst, and optionally recovering the activated acid.
6. A process according to claim 4 wherein the activated acid is combined with an amine to obtain OBA, and optionally recovering the OBA.
7. The process of claim 5, wherein the catalyst is an organic catalyst.
8. The process of claim 5, wherein the catalyst is dimethyl formamide (DMF) or Pyridinium p-toluene sulfonate (PPTS).
9. The process of claim 4, wherein the acid is activated in the presence of a solvent.
10. The process of claim 9, wherein the solvent is selected from a group consisting of C6-12 aromatic hydrocarbon, a C1-4 halogenated hydrocarbon, a C4-8 ether and mixtures thereof.
11. The process of claim 9, wherein the solvent is selected from a group consisting of toluene, CH2Cl2 and THF.
12. The process of claim 9, wherein the solvent is CH2Cl2.
13. The process of claim 9, wherein the solvent is cooled to a temperature of about −40° C. to about 70° C.
14. The process of claim 13, wherein the solvent is cooled to a temperature of about −10° C. to about 10° C.
15. The process of claim 5, wherein the activating agent is SOCl2, CoCl2, DCC(N′-dicyclohexyl carbodiimide) or analogs, HOBT or analogs, or FMOC or analogs.
16. The process of claim 15, wherein the activating agent is SOCl2.
17. The process of claim 5, wherein the activated acid is recovered by removing the solvent.
18. The process of claim 5, wherein the dimethylamine is a salt, and subsequent to its reaction with the activated acid, a second amine is added.
19. The process of claim 18, wherein the amine salt is dimethylamine HCl.
20. The process of claim 19, wherein the second amine is a C3-C9 tertiary amine.
21. The process of claim 20, wherein the second amine is diisopropylamine.
22. The process of claim 17, wherein recovery is done by quenching; washing, filtering, and drying.
23. The process of claim 5, further comprising converting OBA to O-desmethylvenlafaxine or a salt thereof.
24. Protected hydroxyphenyl dimethylamide of the following structure:
Figure US20080183016A1-20080731-C00014
wherein x is a hydroxy protecting group.
25-30. (canceled)
31. A process for preparing compound of claim 24 comprising combining OBA with a suitable hydroxyl protecting agent and optionally a base.
32-39. (canceled)
40. 2-(1-hydroxycyclohexyl)-2-(4-hydroxyphenyl)-N,N-dimethylacetamide (COBA) having the following structure:
Figure US20080183016A1-20080731-C00015
41. (canceled)
42. A process for preparing the compound of claim 40 comprising reacting OBA with cyclohexanone and a base able to form a carbanion and recovering the obtained COBA.
45-53. (canceled)
54. Hydroxyl protected 2-(1-hydroxycyclohexyl)-2-(4-hydroxyphenyl)-N,N-dimethylacetamide (PCOBA) having the following structure:
Figure US20080183016A1-20080731-C00016
wherein x is a hydroxy protecting group.
55. (canceled)
56. A process for preparing the hydroxyl protected 2-(1-hydroxycyclohexyl)-2-(4-hydroxyphenyl)-N,N-dimethylacetamide of claim 54 comprising reacting a hydroxy protected OBA (POBA) with cyclohexanone and a base able to form a carbanion and recovering the obtained PCOBA.
57. A process for preparing ODV (O-desmethylvenlafaxine) comprising converting the COBA of claim 40 or the PCOBA of claim 54 to ODV or a salt thereof.
58-66. (canceled)
67. A process for preparing ODV (O-desmethylvenlafaxine) or salts thereof comprising the steps of: combining OBCarboxy, a catalyst and an acid activating agent to obtain an activated acid; recovering the activated acid, combining it with dimethylamine or a salt thereof and an amine to obtain OBA; reacting the obtained OBA with cyclohexanone and a base able to form a carbanion; recovering the obtained COBA; reacting the obtained COBA, and a reducing agent; and recovering the obtained ODV or a salt thereof.
68. (canceled)
69. A process for preparing ODV (O-desmethylvenlafaxine) or salts thereof comprising the steps of:
(i) preparing OBA from 4-hydroxyphenylacetic acid by a process according to claim 4;
(ii) optionally preparing POBA from OBA by a process according to claim 31;
(iii) preparing COBA from OBA by a process according to claim 42;
(iv) optionally preparing PCOBA from POBA according to claim 56;
(v) converting the COBA or PCOBA to ODV by a process according to claim 57.
70-71. (canceled)
US11/881,826 2006-07-26 2007-07-26 Process for the synthesis of O-desmethylvenlafaxine Abandoned US20080183016A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/881,826 US20080183016A1 (en) 2006-07-26 2007-07-26 Process for the synthesis of O-desmethylvenlafaxine

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US83361606P 2006-07-26 2006-07-26
US83787906P 2006-08-14 2006-08-14
US84399806P 2006-09-11 2006-09-11
US84925506P 2006-10-03 2006-10-03
US84921606P 2006-10-03 2006-10-03
US90663907P 2007-03-12 2007-03-12
US90687907P 2007-03-13 2007-03-13
US11/881,826 US20080183016A1 (en) 2006-07-26 2007-07-26 Process for the synthesis of O-desmethylvenlafaxine

Publications (1)

Publication Number Publication Date
US20080183016A1 true US20080183016A1 (en) 2008-07-31

Family

ID=38924359

Family Applications (4)

Application Number Title Priority Date Filing Date
US11/881,731 Expired - Fee Related US7605290B2 (en) 2006-07-26 2007-07-26 Processes for the synthesis of O-desmethylvenlafaxine
US11/881,825 Abandoned US20080177110A1 (en) 2006-07-26 2007-07-26 Processes for the synthesis of O-desmethylvenlafaxine
US11/881,799 Abandoned US20090062572A1 (en) 2006-07-26 2007-07-26 Processes for the synthesis of O-desmethylvenlafaxine
US11/881,826 Abandoned US20080183016A1 (en) 2006-07-26 2007-07-26 Process for the synthesis of O-desmethylvenlafaxine

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US11/881,731 Expired - Fee Related US7605290B2 (en) 2006-07-26 2007-07-26 Processes for the synthesis of O-desmethylvenlafaxine
US11/881,825 Abandoned US20080177110A1 (en) 2006-07-26 2007-07-26 Processes for the synthesis of O-desmethylvenlafaxine
US11/881,799 Abandoned US20090062572A1 (en) 2006-07-26 2007-07-26 Processes for the synthesis of O-desmethylvenlafaxine

Country Status (7)

Country Link
US (4) US7605290B2 (en)
EP (4) EP1934168A2 (en)
JP (3) JP2008546850A (en)
KR (3) KR101019455B1 (en)
CA (1) CA2656161A1 (en)
IL (1) IL196403A0 (en)
WO (1) WO2008013990A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100076086A1 (en) * 2007-01-31 2010-03-25 Merck Development Centre Private Limited Plot 1 A/2 Process for the preparation of o-desmethyl venlafaxine
CN101781221A (en) * 2010-02-11 2010-07-21 上海凯米侬医药科技有限公司 Preparation method of O-desmethylvenlafaxine

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007016179A (en) * 2006-04-17 2008-03-11 Teva Pharma Polymorphic forms of tegaserod maleate.
EP1934168A2 (en) * 2006-07-26 2008-06-25 Teva Pharmaceutical Industries Ltd Tridesmethylvenlafaxine and processes for the synthesis of o-desmethylvenlafaxine
US20080221356A1 (en) * 2006-07-26 2008-09-11 Valerie Niddam-Hildesheim Processes for the synthesis of O-desmethylvenlafaxine
US20090137846A1 (en) * 2006-07-26 2009-05-28 Valerie Niddam-Hildesheim Processes for the synthesis of O-Desmethylvenlafaxine
US20090069601A1 (en) * 2006-07-26 2009-03-12 Valerie Niddam-Hildesheim Processes for the synthesis of O-desmethylvenlafaxine
EP2061750A2 (en) * 2006-08-04 2009-05-27 Medichem, S.A. Improved process for synthesizing desvenlafaxine free base and salts or solvates thereof
WO2010008735A2 (en) * 2008-06-16 2010-01-21 Teva Pharmaceutical Industries Ltd. Solid states of o-desmethylvenlaf axine salts
EP2539313A2 (en) * 2010-03-29 2013-01-02 Pliva Hrvatska D.O.O. Crystal forms of o-desmethylvenlafaxine fumarate
JP5858581B2 (en) * 2012-09-27 2016-02-10 国立大学法人 東京大学 Method for producing indole 3-carboxylic acids
CN108499614B (en) * 2018-04-28 2021-06-04 西南医科大学附属医院 Method for preparing drug intermediate for central nervous system from modified nickel catalytic material

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4283418A (en) * 1979-03-01 1981-08-11 Ono Pharmaceutical Co., Ltd. Guanidinobenzoic acid derivatives and process for their preparation
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US6197828B1 (en) * 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
US20020022662A1 (en) * 1999-06-15 2002-02-21 American Home Products Corporation Enantiomers of O-desmethyl venlafaxine
US6350912B1 (en) * 2001-02-28 2002-02-26 Council Of Scientific And Industrial Research One pot process for the preparation of 1-[2-dimethylamino-(4-methoxyphenyl)-ethyl]cyclohexanol
US20020120164A1 (en) * 2001-02-28 2002-08-29 Council Of Scientific And Industrial Research Process for the preparation of 1-[cyano(aryl)methyl] cyclohexanol
US6673838B2 (en) * 2001-02-12 2004-01-06 Wyeth Succinate salt of O-desmethyl-venlafaxine
US6689912B2 (en) * 2001-12-04 2004-02-10 Wyeth Methods for preparing O-desmethylvenlafaxine
US20040106818A1 (en) * 2002-11-29 2004-06-03 Lan Zhiyin Process for the preparation of cyclohexanol derivatives
US20040181093A1 (en) * 2003-03-11 2004-09-16 Wyeth Process for preparation of phenethylamine derivatives
US20050009870A1 (en) * 2003-07-11 2005-01-13 Sher Philip M. Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US20050197392A1 (en) * 1999-04-06 2005-09-08 Sepracor Inc. O-desmethylvenlafaxine and methods of preparing and using the same
US7026513B2 (en) * 2002-03-26 2006-04-11 Nicholas Piramal India Limited Manufacture of phenyl ethylamine compounds, in particular venlafaxine
US20070135449A1 (en) * 2005-12-05 2007-06-14 Wyeth Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols
US20080221356A1 (en) * 2006-07-26 2008-09-11 Valerie Niddam-Hildesheim Processes for the synthesis of O-desmethylvenlafaxine
US20090069601A1 (en) * 2006-07-26 2009-03-12 Valerie Niddam-Hildesheim Processes for the synthesis of O-desmethylvenlafaxine
US20090137846A1 (en) * 2006-07-26 2009-05-28 Valerie Niddam-Hildesheim Processes for the synthesis of O-Desmethylvenlafaxine
US7605290B2 (en) * 2006-07-26 2009-10-20 Teva Pharmaceutical Industries Ltd. Processes for the synthesis of O-desmethylvenlafaxine

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3494954A (en) * 1967-06-19 1970-02-10 Cutter Lab 3,3-bis(phenyl)-2-(4-hydroxyphenyl)acrylonitriles
JPS5331642A (en) * 1976-09-02 1978-03-25 Sumitomo Chem Co Ltd Preparation of benzyl cyanides
JPS55115863A (en) * 1979-03-01 1980-09-06 Ono Pharmaceut Co Ltd Guanidinobenzoic acid derivative and its preparation
IE56324B1 (en) 1982-12-13 1991-06-19 American Home Prod Phenethylamine derivatives and intermediates therefor
ZA839073B (en) * 1982-12-13 1984-09-26 American Home Prod Phenethylamine derivatives and intermediates therefor
JP4201916B2 (en) * 1999-05-10 2008-12-24 日本化学工業株式会社 Optically active 1,2-bis (dialkylphosphino) benzene derivative, process for producing the same, and rhodium metal complex having the compound as a ligand
CN1240206A (en) * 1999-06-17 2000-01-05 华东理工大学 Process for preparing 1[2-(dimethyamino)-1-(4-methoxyphenyl)ethyl] cyclohexanol hydrochloridumi
DE10065442A1 (en) 2000-12-27 2002-07-04 Bayer Ag Improved process for the preparation of 2- (4-trifluoromethoxyphenyl) ethylamine and 4-bromomethyl and 4-chloromethyl-1-trifluoromethoxy-benzene
KR20030000217A (en) * 2001-06-22 2003-01-06 와이어쓰 Process for the preparation of cyclohexanol derivatives
WO2005049560A2 (en) 2003-09-29 2005-06-02 Sun Pharmaceutical Industries Limited Process for the preparation of anti-depressant compound
CN101238094A (en) 2005-06-29 2008-08-06 Wyeth公司 Process for the preparation of 1-[cyano(4-hydroxyphenyl)methyl]cyclohexanol compounds
MX2008000249A (en) 2005-07-06 2008-03-18 Sepracor Inc Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders.
MX2008000680A (en) * 2005-07-15 2008-03-14 Wyeth Corp Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof.
WO2007071404A1 (en) 2005-12-20 2007-06-28 Synthon B.V. Process for making desvenlafaxine
JP2008546718A (en) 2006-04-17 2008-12-25 テバ ファーマシューティカル インダストリーズ リミティド Substantially pure O-desmethylvenlafaxine and method for its preparation.
EP1870395A1 (en) * 2006-06-19 2007-12-26 KRKA, D.D., Novo Mesto Process for preparation of o-desmethylvenlafaxine and its analogue
EP2061750A2 (en) 2006-08-04 2009-05-27 Medichem, S.A. Improved process for synthesizing desvenlafaxine free base and salts or solvates thereof

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4283418A (en) * 1979-03-01 1981-08-11 Ono Pharmaceutical Co., Ltd. Guanidinobenzoic acid derivatives and process for their preparation
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US6197828B1 (en) * 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
US20050197392A1 (en) * 1999-04-06 2005-09-08 Sepracor Inc. O-desmethylvenlafaxine and methods of preparing and using the same
US20020022662A1 (en) * 1999-06-15 2002-02-21 American Home Products Corporation Enantiomers of O-desmethyl venlafaxine
US6673838B2 (en) * 2001-02-12 2004-01-06 Wyeth Succinate salt of O-desmethyl-venlafaxine
US7026508B2 (en) * 2001-02-12 2006-04-11 Wyeth Succinate salt of O-desmethyl-venlafaxine
US6350912B1 (en) * 2001-02-28 2002-02-26 Council Of Scientific And Industrial Research One pot process for the preparation of 1-[2-dimethylamino-(4-methoxyphenyl)-ethyl]cyclohexanol
US20020120164A1 (en) * 2001-02-28 2002-08-29 Council Of Scientific And Industrial Research Process for the preparation of 1-[cyano(aryl)methyl] cyclohexanol
US6689912B2 (en) * 2001-12-04 2004-02-10 Wyeth Methods for preparing O-desmethylvenlafaxine
US7026513B2 (en) * 2002-03-26 2006-04-11 Nicholas Piramal India Limited Manufacture of phenyl ethylamine compounds, in particular venlafaxine
US20040106818A1 (en) * 2002-11-29 2004-06-03 Lan Zhiyin Process for the preparation of cyclohexanol derivatives
US20040181093A1 (en) * 2003-03-11 2004-09-16 Wyeth Process for preparation of phenethylamine derivatives
US20050009870A1 (en) * 2003-07-11 2005-01-13 Sher Philip M. Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US20070135449A1 (en) * 2005-12-05 2007-06-14 Wyeth Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols
US20080221356A1 (en) * 2006-07-26 2008-09-11 Valerie Niddam-Hildesheim Processes for the synthesis of O-desmethylvenlafaxine
US20090069601A1 (en) * 2006-07-26 2009-03-12 Valerie Niddam-Hildesheim Processes for the synthesis of O-desmethylvenlafaxine
US20090137846A1 (en) * 2006-07-26 2009-05-28 Valerie Niddam-Hildesheim Processes for the synthesis of O-Desmethylvenlafaxine
US7605290B2 (en) * 2006-07-26 2009-10-20 Teva Pharmaceutical Industries Ltd. Processes for the synthesis of O-desmethylvenlafaxine

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100076086A1 (en) * 2007-01-31 2010-03-25 Merck Development Centre Private Limited Plot 1 A/2 Process for the preparation of o-desmethyl venlafaxine
CN101781221A (en) * 2010-02-11 2010-07-21 上海凯米侬医药科技有限公司 Preparation method of O-desmethylvenlafaxine

Also Published As

Publication number Publication date
KR20080037713A (en) 2008-04-30
KR20080037714A (en) 2008-04-30
EP2046725A2 (en) 2009-04-15
EP1934168A2 (en) 2008-06-25
EP1934167A2 (en) 2008-06-25
WO2008013990A3 (en) 2008-03-27
JP2008546850A (en) 2008-12-25
KR20080037715A (en) 2008-04-30
US20080139849A1 (en) 2008-06-12
JP2008088159A (en) 2008-04-17
JP2008044936A (en) 2008-02-28
EP1917237A2 (en) 2008-05-07
IL196403A0 (en) 2009-11-18
KR101019453B1 (en) 2011-03-07
KR101019455B1 (en) 2011-03-07
WO2008013990A2 (en) 2008-01-31
CA2656161A1 (en) 2008-01-31
US20080177110A1 (en) 2008-07-24
US20090062572A1 (en) 2009-03-05
US7605290B2 (en) 2009-10-20
KR101019454B1 (en) 2011-03-07

Similar Documents

Publication Publication Date Title
US20080183016A1 (en) Process for the synthesis of O-desmethylvenlafaxine
NZ260857A (en) Alkyl n-(3-alkoxycarbonyloxy-3-phenyl-propyl)- n-methyl-carbamates
US20100113778A1 (en) Process for preparing o-chloromethylphenylglyoxylic esters, improved process for preparing (e)-2-(2-chloromethylphenyl)-2-alkoximinoacetic esters, and novel intermediates for their preparation
EP2349976B1 (en) A process for producing (s)-3-[(1-dimethylamino)ethyl]phenyl-n-ethyl-n-methyl-carbamate via novel intermediates
US6506941B1 (en) Venlafaxine production process
WO2009084037A2 (en) Novel process for preparation of o-desmethylvenlafaxine
US9321712B2 (en) Process for the preparation of ospemifene
MX2008004089A (en) Processes for the synthesis of o-desmethylvenlafaxine
TW200405809A (en) Process for preparing (S)-(+)-2-(substituted phenyl)-2-hydroxy-ethyl carbamates
JP4763788B2 (en) Method for synthesizing O-desmethylvenlafaxine
US20150105567A1 (en) Optically active axially chiral alpha-allenic alcohol, synthesis method and use thereof
US20120253074A1 (en) Process for the preparation of o-desmethyl-venlafaxine and salts thereof
JP4829418B2 (en) Optically active halohydrin derivative and method of using the same
ES2288376A1 (en) Process for obtaining valine derivatives useful for obtaining a pharmaceutically active compound
CA2656167A1 (en) Processes for the synthesis of o-desmethylvenlafaxine
KR100647068B1 (en) Process for preparing racemic n,n-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine
JP4039026B2 (en) Method for producing 3-amino-2-thiophenecarboxylic acid ester
JP4000278B2 (en) Process for producing ω-bromoalkylmalonic acid and ω-bromoalkylcarboxylic acid
WO2000050379A1 (en) Process for the preparation of (1r, 2s, 4r) -(-) -2 - (2 -dimethylaminoethoxy) -2 -phenyl -1,7,7 - trimethylbicyclo [2.2.1] heptane
US20050137416A1 (en) Process and intermediates for preparing a cyclohexylnitrile
JP2004500372A (en) Methods and intermediates for preparing cyclohexylnitrile
EP1319646A1 (en) Process for preparation of 3,5-bisalkylphenols
AU2004205303A1 (en) Process and intermediates for preparing a cyclohexylnitrile
JP2003226676A (en) Alfa-alkyl-fluoro, trifluoromethyl or trifluoromethoxy- substituted benzylamine, n-alkyl alfa-alkyl-fluoro, trifluoro- or trifluoromethoxy-substituted benzylamine
JPH09249641A (en) Fluorinated vitamin d derivative and its production

Legal Events

Date Code Title Description
AS Assignment

Owner name: TEVA PHARMACEUTICAL INDUSTRIES LTD., ISRAEL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NIDDAM-HILDESHEIM, VALERIE;NIDAM, TAMAR;REEL/FRAME:020649/0342;SIGNING DATES FROM 20070924 TO 20070925

Owner name: TEVA PHARMACEUTICALS USA, INC., PENNSYLVANIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TEVA PHARMACEUTICAL INDUSTRIES LTD.;REEL/FRAME:020649/0359

Effective date: 20071015

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION